


# The Growing Inhaled Nitric Oxide Market: A Breath of Fresh Air for Respiratory Treatment

PORTLAND, OR, UNITED STATES,  
February 11, 2025 /EINPresswire.com/  
-- Market Overview

The global [inhaled nitric oxide \(iNO\) market](#) is experiencing steady growth, valued at \$0.8 billion in 2022 and projected to double to \$1.6 billion by 2032, growing at a CAGR of 7.7% from 2023 to 2032. This growth is fueled by the increasing incidence of respiratory disorders, advancements in medical infrastructure, and greater adoption of iNO therapy in neonatal care.



Get a Sample Copy of this Report: <https://www.alliedmarketresearch.com/request-sample/3020>

## Understanding Inhaled Nitric Oxide (iNO)

Inhaled nitric oxide is a therapeutic gas used in the treatment of pulmonary conditions due to its vasodilatory properties, helping relax blood vessels in the lungs and improve oxygenation. Key medical applications include:

- Persistent Pulmonary Hypertension in Newborns (PPHN)
- Acute Respiratory Distress Syndrome (ARDS)
- Chronic Obstructive Pulmonary Disease (COPD)

## Key Market Drivers

Several factors contribute to the expanding inhaled nitric oxide market:

### 1. Rising Preterm Birth Rates

- Preterm birth rates range between 5% and 18% globally, with developing nations experiencing the highest infant mortality.
- Babies born before 32 weeks are at high risk of respiratory distress syndrome (RDS), increasing the demand for iNO therapy.

## 2. Increasing Prevalence of Respiratory Disorders

- Chronic respiratory conditions like COPD, asthma, and ARDS are on the rise due to factors such as pollution, smoking, and aging populations.
- In 2022, 2.5% of Australians (638,100 people) were diagnosed with COPD, showcasing the rising global burden of lung diseases.

## 3. Advancements in Healthcare Infrastructure

- Expansion of healthcare facilities and neonatal intensive care units (NICUs) in developing nations is driving market growth.
- Improved availability of specialized delivery systems enhances treatment accessibility.

## 4. Research & Development (R&D) Initiatives

- Continuous R&D investments are exploring novel applications of iNO beyond neonatal care, including potential treatments for COVID-19 and pulmonary hypertension.
- Companies are focusing on optimizing delivery mechanisms for improved patient outcomes.

## Market Challenges

Despite its strong growth trajectory, the iNO market faces hurdles, including:

- High Cost of Therapy: The complex manufacturing process and specialized equipment make iNO therapy expensive, limiting access in low-income regions.
- Limited Awareness: In some countries, lack of awareness among healthcare professionals and patients hampers market penetration.

## Market Segmentation

### By Application

- Neonatal Respiratory Treatment: Largest segment, driven by high demand for treating PPHN and RDS.
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Others

### By Region

- North America: Largest market share in 2022, supported by advanced healthcare infrastructure.
- Europe: Strong growth due to rising neonatal and respiratory treatments.
- Asia-Pacific: Expected to grow at the fastest CAGR, driven by increasing healthcare investments.
- LAMEA (Latin America, Middle East, and Africa): Gradual expansion due to improving medical facilities.

## Competitive Landscape

The iNO market is highly competitive, with key players focusing on patents, strategic

partnerships, and R&D investments to maintain market leadership. Major companies include:

- Air Liquide S.A
- Linde Plc
- Mallinckrodt Plc
- Vero Biotech LLC
- Nippon Sanso Holdings Corporation

#### Recent Developments

- April 2020: Linde Plc won a nitric oxide patent in the U.S. and contributed to COVID-19 research.
- January 2021: SOL Group expanded its footprint in India by increasing its stake in SICGILSOL.

#### Future Outlook

The inhaled nitric oxide market is set for substantial growth, driven by:

- Expanding applications in neonatal and respiratory care.
- Increasing healthcare investments in developing nations.
- Ongoing R&D to explore new medical uses.

#### Key Takeaways

- The iNO market is projected to reach \$1.6 billion by 2032, growing at 7.7% CAGR.
- Neonatal respiratory treatment remains the dominant application.
- North America leads the market, but Asia-Pacific is expected to grow the fastest.
- Despite challenges like high costs and limited awareness, technological advancements and increased healthcare access present significant opportunities.

#### Conclusion

As demand for advanced respiratory treatments continues to rise, inhaled nitric oxide is positioned to become a game-changing solution for various pulmonary conditions. With ongoing R&D, expanding healthcare infrastructure, and increasing awareness, the market is set for a transformative decade ahead.

Enquire Before Buying: <https://www.alliedmarketresearch.com/purchase-enquiry/3020>

David Correa

Allied Market Research

+ + 1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/784994196>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.